# i" W4 B9 i2 S' `5 V! i5 l临床上有依维莫司联合EGFR TKI作为易/特耐药之后的方案的研究:, I# \4 }" p" t, B/ d2 ?( w u
Everolimus and erlotinib as second- or third-line therapy in patients with advanced non-small-cell lung cancer.# _3 G6 v* A8 A1 D. ?* d http://www.ncbi.nlm.nih.gov/pubmed/22968184. V/ y" r* T/ u' S! T7 b